Brookline Capital Markets Comments on ADIL Q2 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Analysts at Brookline Capital Markets issued their Q2 2026 earnings per share (EPS) estimates for shares of Adial Pharmaceuticals in a research report issued on Monday, May 11th. Brookline Capital Markets analyst K. Dolliver forecasts that the company will post earnings of ($1.40) per share for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($7.34) per share. Brookline Capital Markets also issued estimates for Adial Pharmaceuticals’ Q3 2026 earnings at ($1.41) EPS and Q4 2026 earnings at ($1.42) EPS.

ADIL has been the subject of a number of other research reports. UBS Group set a $8.00 price target on Adial Pharmaceuticals in a report on Wednesday, February 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Adial Pharmaceuticals in a report on Monday, April 20th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.75.

Adial Pharmaceuticals Stock Up 0.7%

Shares of ADIL stock opened at $1.44 on Tuesday. The stock has a market cap of $2.06 million, a PE ratio of -0.10 and a beta of 1.27. The business has a 50-day simple moving average of $1.74 and a 200-day simple moving average of $4.65. Adial Pharmaceuticals has a 52-week low of $1.38 and a 52-week high of $18.90.

Adial Pharmaceuticals (NASDAQ:ADIL) last posted its quarterly earnings results on Friday, May 8th. The company reported ($1.48) earnings per share for the quarter, beating the consensus estimate of ($2.73) by $1.25.

Institutional Investors Weigh In On Adial Pharmaceuticals

A number of large investors have recently made changes to their positions in ADIL. Armistice Capital LLC purchased a new position in Adial Pharmaceuticals in the fourth quarter worth approximately $562,000. Citadel Advisors LLC purchased a new position in Adial Pharmaceuticals in the third quarter worth approximately $51,000. Finally, Jane Street Group LLC grew its position in Adial Pharmaceuticals by 887.3% in the fourth quarter. Jane Street Group LLC now owns 121,841 shares of the company’s stock worth $27,000 after acquiring an additional 109,500 shares during the period. 16.41% of the stock is currently owned by hedge funds and other institutional investors.

Adial Pharmaceuticals Company Profile

Adial Pharmaceuticals, Inc, incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy.

The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence.